Turkey's choice Sinovac vaccine far less effective, says new Brazilian study

The CoronaVac COVID-19 vaccine developed by China's Sinovac Biotech has a general efficacy of less than 60% in its clinical trial in Brazil, Reuters reported on Monday.

São Paulo's Bhutantan biomedical center partnered with Sinovac to produce the vaccine in Brazil planned to release general efficacy results on Tuesday as it seeks emergency use for the shot from health regulator Anvisa. It called the report "purely speculative", Reuters said.

Minister of Health of Turkey Fahrettin Koca said on January 7 in a statement that the efficacy rate of 78 percent in the Brazil trial is valid in moderate cases while the vaccine provides 100 percent efficacy in severe cases. Turkey argued that the CoronaVac provides 91.25 percent efficacy based on the country's interim results of a phase 3 trial conducted with volunteers between the ages of 18-59.

Turkey has bought 50 million doses of the CoronaVac COVID-19 vaccine. So far 3 million of them arrived Turkey. According to World Health Organization, the vaccines need to be minimum 50 percent effective to be eligible for mass use, according to Prof. Vedat Bulut, Turkish Medical Association (TTB) Secretary General.

Germany-based neuroscientist Çağhan Kızıl, referencing to the same findings and attaching a screen shot of a Brazilian TV, said that the efficacy rate of the Chinese vaccine actually stands at 50.38 percent.